Citadel Advisors
DNLI icon

Citadel Advisors’s Denali Therapeutics DNLI Stock Holding History

Citadel Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.99M Buy
77,300
+37,000
+92% +$760K ﹤0.01% 6574
2026
Q1 		$774K Buy
40,300
+13,200
+49% +$263K ﹤0.01% 8274
2025
Q4 		$447K Buy
27,100
+15,500
+134% +$262K ﹤0.01% 9300
2025
Q3 		$168K Sell
11,600
-8,800
-43% -$126K ﹤0.01% 11437
2025
Q2 		$285K Hold
20,400
– – ﹤0.01% 9925
2025
Q1 		$277K Buy
20,400
+1,000
+5% +$19.2K ﹤0.01% 9775
2024
Q4 		$395K Buy
19,400
+5,000
+35% +$128K ﹤0.01% 9082
2024
Q3 		$419K Sell
14,400
-1,100
-7% -$27.3K ﹤0.01% 8642
2024
Q2 		$360K Sell
15,500
-3,500
-18% -$67.2K ﹤0.01% 8752
2024
Q1 		$390K Buy
19,000
+12,400
+188% +$233K ﹤0.01% 8916
2023
Q4 		$142K Sell
6,600
-4,000
-38% -$79.2K ﹤0.01% 10472
2023
Q3 		$219K Sell
10,600
-100
-0.9% -$2.54K ﹤0.01% 9735
2023
Q2 		$316K Sell
10,700
-11,700
-52% -$329K ﹤0.01% 8937
2023
Q1 		$516K Sell
22,400
-3,200
-13% -$88.1K ﹤0.01% 8236
2022
Q4 		$712K Buy
25,600
+10,700
+72% +$318K ﹤0.01% 7507
2022
Q3 		$457K Sell
14,900
-4,400
-23% -$143K ﹤0.01% 8655
2022
Q2 		$568K Buy
19,300
+9,700
+101% +$254K ﹤0.01% 8356
2022
Q1 		$309K Sell
9,600
-4,100
-30% -$141K ﹤0.01% 10519
2021
Q4 		$611K Sell
13,700
-8,100
-37% -$384K ﹤0.01% 9187
2021
Q3 		$1.1M Buy
21,800
+3,900
+22% +$220K ﹤0.01% 7898
2021
Q2 		$1.4M Buy
17,900
+600
+3% +$37.1K ﹤0.01% 7462
2021
Q1 		$988K Sell
17,300
-16,400
-49% -$1.1M ﹤0.01% 8143
2020
Q4 		$2.82M Buy
33,700
+19,200
+132% +$1.16M ﹤0.01% 4682
2020
Q3 		$520K Buy
+14,500
New +$437K ﹤0.01% 7235

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors's DNLI Position: Q2 2026 in Review

Citadel Advisors reduced its Denali Therapeutics (DNLI) stake by 63% in Q2 2026, selling an estimated $2.35M and leaving 66,971 shares worth $1.72M. The position accounts for ﹤0.01% of the portfolio, ranked #6907.

Citadel Advisors first reported a position in DNLI in Q2 2018 and has held it in 30 quarters since. The position peaked at $31.7M in Q1 2023. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Citadel Advisors held 66,971 shares of Denali Therapeutics worth $1.72M as of Q2 2026.
  • Citadel Advisors sold 114,446 Denali Therapeutics shares in Q2 2026, an estimated $2.35M.
  • Denali Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #6907 holding.
  • Citadel Advisors first reported a position in Denali Therapeutics in Q2 2018 and has held it in 30 quarters since.
  • Citadel Advisors's Denali Therapeutics position peaked at $31.7M in Q1 2023.
  • 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.